Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Attruby is the first and only approved product with a label…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneer of…
AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress…
Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance
NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Fourth Frontier, a medical technology…
Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance
NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Fourth Frontier, a medical technology…
Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance
NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Fourth Frontier, a medical technology…